Alphacentric Lifesci Healthcare Fund Investor Sentiment

LYFCX Fund  USD 13.03  0.13  1.01%   
Slightly above 51% of Alphacentric Lifesci's investor base is interested to short. The analysis of overall sentiment of trading Alphacentric Lifesci Healthcare mutual fund suggests that many investors are impartial at this time. Alphacentric Lifesci's investing sentiment can be driven by a variety of factors including economic data, Alphacentric Lifesci's earnings reports, geopolitical events, and overall market trends.
  
over a year ago at news.google.com         
Morgan Stanley Maintains Airsculpt Technologies Equal ... - Nasdaq
Google News at Macroaxis
over a year ago at news.google.com         
Morgan Stanley Maintains Airsculpt Technologies Equal ... - Nasdaq
Google News at Macroaxis
over a year ago at news.google.com         
Unusual Call Option Trade in Airsculpt Technologies Worth ... - Nasdaq
Google News at Macroaxis
a day ago at news.google.com         
Milestone Asset Management LLC Has 2.06 Million Stock Holdings in Gilead Sciences, Inc. - MarketBeat
Google News at Macroaxis
few days ago at www.macroaxis.com         
Disposition of 187 shares by Deborah Telman of Gilead Sciences at 93.07 subject to Rule 16b-3
Macroaxis News
over a week ago at finance.yahoo.com         
Merck Co., Inc. A Bull Case Theory
Yahoo News
over a week ago at thelincolnianonline.com         
Liberty One Investment Management LLC Sells 7,350 Shares of Gilead Sciences, Inc.
news
over a week ago at thelincolnianonline.com         
Gateway Investment Advisers LLC Trims Stock Position in Gilead Sciences, Inc.
news
over a week ago at medcitynews.com         
Galapagos CEO Tells JPM Audience the Rationale for Planned Business Separation
news
over two weeks ago at statnews.com         
STAT Pharmalittle Were reading about lower-priced Zepbound vials, monkey shipments from Cambodia, an...
news
over two weeks ago at thelincolnianonline.com         
USA Financial Formulas Takes Position in Gilead Sciences, Inc.
news
over two weeks ago at zacks.com         
Gilead Sciences Rises Yet Lags Behind Market Some Facts Worth Knowing
zacks News
over two weeks ago at finance.yahoo.com         
Gilead Sciences, US government settle patent case over HIV prevention drugs
Yahoo News
a day ago at news.google.com         
March 14th Options Now Available For Vertex Pharmaceuticals - Nasdaq
Google News at Macroaxis
few days ago at news.google.com         
Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10 - Business Wir...
Google News at Macroaxis
over a week ago at thelincolnianonline.com         
Diversify Wealth Management LLC Raises Stake in Vertex Pharmaceuticals Incorporated
news
over a week ago at finance.yahoo.com         
3 Items That Could Get Less Expensive If Trump Lowers Corporate Taxes
Yahoo News
over a week ago at finance.yahoo.com         
Recursion Pharmaceuticals, Inc. Revolutionizing Drug Discovery with AI and Strategic Collaborations ...
Yahoo News
over a week ago at finance.yahoo.com         
CRISPR Therapeutics Stock Falls 34 percent in a Year Time to Buy or Sell?
Yahoo News
over two weeks ago at investing.com         
CRISPR Therapeutics SWOT analysis gene editing pioneers stock faces pivotal year
Investing News at Macroaxis
over two weeks ago at finance.yahoo.com         
Malayala Manorama Strengthens IT Infrastructure with Hitachi Vantara to Ensure 100 percent Data Avai...
Yahoo News
over two weeks ago at investors.com         
Acquisition by Sachs Bruce I of 111 shares of Vertex Pharmaceuticals subject to Rule 16b-3
Investors Business Daily at Macroaxis
over two weeks ago at investing.com         
Vertex Pharmaceuticals SWOT analysis stock outlook balances innovation and valuation
Investing News at Macroaxis
few days ago at news.google.com         
Viracta Therapeutics strikes deal to avoid default - Investing.com
Google News at Macroaxis
over a month ago at news.google.com         
Viracta stock falls on strategic review - Seeking Alpha
Google News at Macroaxis
over a month ago at investing.com         
Viracta Therapeutics SWOT analysis stock focus narrows amid pipeline shift
Investing News at Macroaxis
over two months ago at investing.com         
Viracta Therapeutics faces Nasdaq delisting risk
Investing News at Macroaxis
over two months ago at news.google.com         
VIRX stock touches 52-week low at 0.15 amid market challenges - Investing.com
Google News at Macroaxis
over two months ago at finance.yahoo.com         
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Developmen...
Yahoo News
over three months ago at news.google.com         
Viracta Therapeutics SWOT analysis narrowed focus shapes stock outlook - Investing.com
Google News at Macroaxis
over three months ago at www.macroaxis.com         
Disposition of 9034 shares by Pomerantz Roger of Viracta Therapeutics subject to Rule 16b-3
Macroaxis News
over three months ago at finance.yahoo.com         
Thornburg Names Heads of Equities and Fixed Income
Yahoo News
over three months ago at investorplace.com         
VIRX Stock Earnings Viracta Therapeutics Beats EPS for Q2 2024
sbwire news
3 days ago at news.google.com         
KBC Group NV Purchases 7,169 Shares of United Therapeutics Co. - MarketBeat
Google News at Macroaxis
over a week ago at simplywall.st         
United Therapeutics Corporation Doing What It Can To Lift Shares
Simply Wall St News at Macroaxis
over two weeks ago at finance.yahoo.com         
OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistica...
Yahoo News
over two weeks ago at finance.yahoo.com         
Heres Why United Therapeutics is a Strong Growth Stock
Yahoo News
over two weeks ago at finance.yahoo.com         
Are Medical Stocks Lagging United Therapeutics This Year?
Yahoo News
over three weeks ago at finance.yahoo.com         
UTHR vs. STVN Which Stock Is the Better Value Option?
Yahoo News
over three weeks ago at gurufocus.com         
United Therapeutics Corp to Present at J.P. Morgan Healthcare Conference
Gurufocus Stories at Macroaxis
over three weeks ago at thelincolnianonline.com         
Insider Selling United Therapeutics Co. Director Sells 90,721.35 in Stock
news
over a month ago at businesswire.com         
OS Therapies Announces Closing of 6 Million Private Placement
businesswire News
over a month ago at simplywall.st         
Investing in United Therapeutics five years ago would have delivered you a 316 percent gain
Simply Wall St News at Macroaxis
a day ago at www.macroaxis.com         
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
Macroaxis News
few days ago at www.macroaxis.com         
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
Macroaxis News
six days ago at www.macroaxis.com         
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
Macroaxis News
over a week ago at www.macroaxis.com         
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
Macroaxis News
over a week ago at www.macroaxis.com         
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
Macroaxis News
over two weeks ago at finance.yahoo.com         
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
Yahoo News
over two weeks ago at thelincolnianonline.com         
Sarepta Therapeutics Reports Strong Preliminary Financial Results for 2024
news
over two weeks ago at finance.yahoo.com         
Sarepta Therapeutics Reports Preliminary Fourth Quarter and Full-Year 2024 Net Product Revenue
Yahoo News
over two weeks ago at businesswire.com         
Sarepta Therapeutics Reports Preliminary Fourth Quarter and Full-Year 2024 Net Product Revenue
businesswire News
over two weeks ago at seekingalpha.com         
Sarepta preliminary Q4 revenue beats, but full year just misses
seekingalpha News
a day ago at news.google.com         
Implied Volatility Surging for Regeneron Pharmaceuticals Stock Options - MSN
Google News at Macroaxis
over a week ago at businesswire.com         
REGN INVESTOR ALERT Bronstein, Gewirtz Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. I...
businesswire News
over a week ago at thelincolnianonline.com         
Regeneron Pharmaceuticals Provides Business Updates and Highlights from 43rd Annual J.P. Morgan Heal...
news
over a week ago at gurufocus.com         
REGN INVESTOR ALERT Robbins Geller Rudman Dowd LLP Announces that Regeneron ...
Gurufocus Stories at Macroaxis
over a week ago at patch.com         
51 CA Teens Awarded 2,000 In 2025 Regeneron Science Talent Search
patch News
over a week ago at thelincolnianonline.com         
Regeneron Pharmaceuticals, Inc. Shares Sold by Boston Common Asset Management LLC
news
over two weeks ago at gurufocus.com         
Regeneron Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending Contact Levi ...
Gurufocus Stories at Macroaxis
over two weeks ago at fortune.com         
Pharma giant Regeneron is spending 119.5M on the worlds largest, most diverse genetic database using...
news
over two weeks ago at gurufocus.com         
The Gross Law Firm Notifies Regeneron Pharmaceuticals, Inc. ...
Gurufocus Stories at Macroaxis
over two weeks ago at insidermonkey.com         
Jim Cramer on Regeneron Pharmaceuticals, Inc. Stock That Seems To Have Disappointed People. Bizarre
insidermonkey News
a day ago at news.google.com         
UniQure Gets Favorable Recommendation From Data Monitoring Committee AMT-162 Trial to Treat Amyotrop...
Google News at Macroaxis
over two weeks ago at news.google.com         
Sanders Morris Harris LLC Buys 34,034 Shares of uniQure - MarketBeat
Google News at Macroaxis
over two weeks ago at finance.yahoo.com         
Heres Why uniQure N.V. Is Skyrocketing
Yahoo News
over two weeks ago at www.macroaxis.com         
Acquisition by Springhorn Jeremy P. of 17060 shares of Uniqure NV at 20.18 subject to Rule 16b-3
Macroaxis News
over three weeks ago at thelincolnianonline.com         
uniQure Shares Down 3.5 percent Whats Next?
news
over a month ago at fool.com         
Up 152 percent in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?
fool News
over a month ago at thelincolnianonline.com         
uniQure Price Target Raised to 20.00
news
over a month ago at thelincolnianonline.com         
11,699 Shares in uniQure Bought by Quarry LP
news
over a month ago at benzinga.com         
Why Is uniQure Stock Skyrocketing On Tuesday?
benzinga news
over a month ago at bizjournals.com         
Gene therapy developers stock doubles after FDA grants accelerated approval
bizjournals News
over a year ago at news.google.com         
Nivolumab Plus Relatlimab Induces Durable Responses in ... - OncLive
Google News at Macroaxis
a minute ago at finance.yahoo.com         
Merck and GTRI to develop gene therapy for Parkinsons disease
Yahoo News
2 days ago at news.google.com         
Swedbank AB Purchases 130,541 Shares of Merck Co., Inc. - MarketBeat
Google News at Macroaxis
over a week ago at thelincolnianonline.com         
Wealthquest Corp Raises Position in Merck Co., Inc.
news
over a week ago at finance.yahoo.com         
Jim Cramer on Merck Co., Inc. Right Now, The Stocks Well-ensconced A Few Points Around 52-week Low
Yahoo News
over a week ago at finance.yahoo.com         
Is Summit Therapeutics the Best Russell 2000 Stock to Invest in According to Analysts?
Yahoo News
over a week ago at thelincolnianonline.com         
Merck Co., Inc. Shares Acquired by Relyea Zuckerberg Hanson LLC
news
over a week ago at finance.yahoo.com         
Independence Pet Holdings Announces Sabia Schwarzer as Chief Corporate Affairs Officer
Yahoo News
over two weeks ago at finance.yahoo.com         
Merck Falls 9 percent in 3 Months Buy, Hold or Sell the Stock?
Yahoo News
over two weeks ago at finance.yahoo.com         
FDA Okays LLYs Omvoh for Second Inflammatory Bowel Disease Condition
Yahoo News
over two weeks ago at finance.yahoo.com         
Acute Coronary Syndrome Market to Showcase a Significant Growth at a CAGR of 7.7 percent by 2034 Del...
Yahoo News
a minute ago at simplywall.st         
Jazz Pharmaceuticals investors are sitting on a loss of 20 percent if they invested a year ago
Simply Wall St News at Macroaxis
few days ago at news.google.com         
Pacer Advisors Inc. Purchases 115,102 Shares of Jazz Pharmaceuticals plc - MarketBeat
Google News at Macroaxis
over a week ago at forbes.com         
New York Jazz Club Smoke Celebrates 25 Years
Usa forbes News
over two weeks ago at aol.com         
NBA reschedules Lakers, Clippers games postponed to avoid L.A. wildfires
news
over two weeks ago at nypost.com         
New Orleans Jazz Festival 2025 lineup Lil Wayne, Dave Matthews, more
news
over two weeks ago at finance.yahoo.com         
Primrose Bio to Collaborate with Serum Institute of India to Develop a Novel Multi-Antigen Vaccine
Yahoo News
over three weeks ago at nypost.com         
Morgan Freeman and Al Green stun bargoers with soulful duet of Lets Stay Together on New Years Eve
news
over a month ago at finance.yahoo.com         
Debbies Dream Foundation Curing Stomach Cancer Celebrates a Year of Impactful Programs and Community...
Yahoo News
over a month ago at investing.com         
Akari Therapeutics appoints new CEO and board member
Investing News at Macroaxis
over a month ago at finance.yahoo.com         
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Yahoo News
a day ago at news.google.com         
Robeco Institutional Asset Management B.V. Sells 5,179 Shares of Incyte Co. - MarketBeat
Google News at Macroaxis
over a week ago at finance.yahoo.com         
Disposition of 429 shares by Michael Morrissey of Incyte at 73.47 subject to Rule 16b-3
Yahoo News
over a week ago at thelincolnianonline.com         
Incyte Co. is Shikiar Asset Management Inc.s 8th Largest Position
news
over two weeks ago at finance.yahoo.com         
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 as Monotherapy for Advanced Pancr...
Yahoo News
over two weeks ago at seekingalpha.com         
Disposition of 10692 shares by Stein Steven H of Incyte at 72.46 subject to Rule 16b-3
seekingalpha News
over two weeks ago at finance.yahoo.com         
Has Incyte Outpaced Other Medical Stocks This Year?
Yahoo News
over two weeks ago at thelincolnianonline.com         
Incyte Given Neutral Rating at Cantor Fitzgerald
news
over two weeks ago at zacks.com         
INCY vs. VRTX Which Stock Is the Better Value Option?
zacks News
over three weeks ago at finance.yahoo.com         
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635
Yahoo News
over three weeks ago at businesswire.com         
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635
businesswire News
a day ago at news.google.com         
Heres Why Immunovant, Inc. Will Double in 2025 - Insider Monkey
Google News at Macroaxis
few days ago at news.google.com         
Immunovant stock hits 52-week low at 22. amid market challenges - Investing.com Nigeria
Google News at Macroaxis
over a week ago at thelincolnianonline.com         
Immunovant, Inc. CEO Peter Salzmann Sells 8,767 Shares of Stock
news
over two weeks ago at finance.yahoo.com         
Roivant Sciences buys Immunovant Inc. shares and repurchases its own stock for 336.9 million each
Yahoo News
over two weeks ago at finance.yahoo.com         
Immunovant Announces 450 Million Private Placement
Yahoo News
over two weeks ago at gurufocus.com         
Immunovant Inc Announces 450 Million PIPE Investment
Gurufocus Stories at Macroaxis
over two weeks ago at news.google.com         
Immunovant stock hits 52-week low at 23.86 amid challenges By Investing.com - Investing.com Nigeria
Google News at Macroaxis
over a month ago at thelincolnianonline.com         
Wells Fargo Company Cuts Immunovant Price Target to 45.00
news
over a month ago at www.macroaxis.com         
Insider Trading
Macroaxis News
over a month ago at www.macroaxis.com         
Disposition of 5425 shares by Hughes Douglas J. of Immunovant at 28.54 subject to Rule 16b-3
Macroaxis News
over a year ago at www.macroaxis.com         
Disposition of 110447 shares by Thomas Watkins of Horizon Pharma subject to Rule 16b-3
Macroaxis News
over a year ago at news.google.com         
Institutional owners may consider drastic measures as Vir Biotechnology, Inc.s recent US85m drop add...
Google News at Macroaxis
over a year ago at businesswire.com         
Horizon Therapeutics plc Rule 2.12 Announcement
businesswire News
over a year ago at benzinga.com         
Heres How Much 1000 Invested In Horizon Therapeutics 10 Years Ago Would Be Worth Today
benzinga news
over a year ago at news.google.com         
U.S. FTC allows Amgen to move forward with 27.8 bln Horizon deal - CNBC - Marketscreener.com
Google News at Macroaxis
over a year ago at thelincolnianonline.com         
Toronto Dominion Bank Buys 185,145 Shares of Horizon Therapeutics Public Limited
news
over a year ago at finance.yahoo.com         
Horizon Up as FTC Pauses Acquisition by Amgen Lawsuit
Yahoo News
over a year ago at finance.yahoo.com         
Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocac...
Yahoo News
over a year ago at marketwatch.com         
George Soros has a big stake in this stock but its posted a roughly 9 percent loss this year. Are th...
marketwatch News
over a year ago at thelincolnianonline.com         
Horizon Therapeutics Public Issues Earnings Results
news
over a week ago at news.google.com         
Galapagos downgraded by Barclays, PT cut to 22 - Investing.com
Google News at Macroaxis
over a month ago at thelincolnianonline.com         
Galapagos Stock Price Passes Below 200 Day Moving Average Heres What Happened
news
over two months ago at investing.com         
Galapagos stock downgraded to Reduce on strategic concerns
Investing News at Macroaxis
over two months ago at gurufocus.com         
Stonepine Capital Management Reduces Stake in Evolus Inc
Gurufocus Stories at Macroaxis
over two months ago at thelincolnianonline.com         
Galapagos Sees Large Volume Increase Should You Buy?
news
over three months ago at gurufocus.com         
Galapagos NV Q3 2024 Earnings Call Highlights Strong Cash Position and RD Progress ...
Gurufocus Stories at Macroaxis
over three months ago at seekingalpha.com         
Galapagos Q3 2024 Earnings Preview
seekingalpha News
over three months ago at benzinga.com         
Why Trip.com Group Shares Are Trading Higher By Around 10 Here Are 20 Stocks Moving Premarket
benzinga news
over three months ago at finance.yahoo.com         
Galapagos Up on FDA Nod to Begin Phase III Lymphoma Study
Yahoo News
over three months ago at finance.yahoo.com         
ADAP 2Q24 Earnings Review Tecelra FDA Approval Capital Reload
Yahoo News
2 days ago at news.google.com         
ACADIA Pharmaceuticals SWOT analysis stock outlook amid mixed product performance - MSN
Google News at Macroaxis
over a week ago at thelincolnianonline.com         
Hennion Walsh Asset Management Inc. Boosts Stake in ACADIA Pharmaceuticals Inc.
news
over a week ago at businesswire.com         
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635
businesswire News
over two weeks ago at fool.com.au         
Why did this 1.4 billion ASX 200 healthcare stock just dive 9?
fool News
over two weeks ago at gurufocus.com         
ACADIA Pharmaceuticals Announces Strategic Milestones and Global Expansion Plans
Gurufocus Stories at Macroaxis
over two weeks ago at finance.yahoo.com         
Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency ...
Yahoo News
over three weeks ago at finance.yahoo.com         
Further weakness as ACADIA Pharmaceuticals drops 5.2 percent this week, taking five-year losses to 6...
Yahoo News
over three weeks ago at finance.yahoo.com         
Why ACADIA Pharmaceuticals Inc. Is Skyrocketing
Yahoo News
over a month ago at www.macroaxis.com         
Disposition of 9913 shares by Brendan Teehan of ACADIA Pharmaceuticals subject to Rule 16b-3
Macroaxis News
over a month ago at kalkinemedia.com         
Autism Spectrum Disorder Market, 2034 Scioto Biosciences, ACADIA Pharmaceuticals Inc., Yamo Pharmace...
news
a day ago at news.google.com         
Morgan Stanley lifts Exelixis stock rating to Overweight - MSN
Google News at Macroaxis
six days ago at news.google.com         
Exelixis Stock Faces a Reality Check Will It Hit 41 or Drop to 33 - Yahoo Finance
Google News at Macroaxis
over a week ago at simplywall.st         
Institutional investors control 74 percent of Exelixis, Inc. and were rewarded last week after stock...
Simply Wall St News at Macroaxis
over two weeks ago at thefly.com         
Exelixis price target raised by 7 at JMP Securities, heres why EXEL
news
over two weeks ago at thelincolnianonline.com         
Cooper Financial Group Acquires 1,236 Shares of Exelixis, Inc.
news
over two weeks ago at finance.yahoo.com         
Why Exelixis is Poised to Beat Earnings Estimates Again
Yahoo News
over two weeks ago at kalkinemedia.com         
Exelixis Reports FY24 Results and Provides 2025 Revenue Guidance with Key Developments Ahead
news
over two weeks ago at zacks.com         
Why Exelixis is a Top Value Stock for the Long-Term
zacks News
over two weeks ago at dragonflycap.com         
Top Trade Ideas for the Week of January 13, 2025 The Rest Premium
news
over two weeks ago at globenewswire.com         
EXEL Industries Total number of voting rights and shares at 11.30.2024
Macroaxis News: globenewswire.com
over a year ago at gurufocus.com         
Top 5 4th Quarter Trades of BP PLC
Gurufocus Stories at Macroaxis
over two weeks ago at simplywall.st         
Despite the downward trend in earnings at Collegium Pharmaceutical the stock swells 18, bringing thr...
Simply Wall St News at Macroaxis
over two weeks ago at thelincolnianonline.com         
Collegium Pharmaceuticals Buy Rating Reiterated at HC Wainwright
news
over three weeks ago at gurufocus.com         
Collegium Pharmaceutical Inc Shares Up 11.7 percent on Jan 8
Gurufocus Stories at Macroaxis
over a month ago at thelincolnianonline.com         
Collegium Pharmaceutical Reaches New 1-Year Low Whats Next?
news
over a month ago at news.google.com         
Janus Henderson Group PLC Buys 55,572 Shares of Collegium Pharmaceutical, Inc. - MarketBeat
Google News at Macroaxis
over two months ago at news.google.com         
Rubric Capital Management LP Reduces Holdings in Collegium Pharmaceutical, Inc. - MarketBeat
Google News at Macroaxis
over two months ago at news.google.com         
Is the Options Market Predicting a Spike in Collegium Pharmaceutical Stock - MSN
Google News at Macroaxis
over two months ago at businesswire.com         
PPG inducts five new members into Collegium association, recognizing technology innovations aligned ...
businesswire News
over two months ago at simplywall.st         
Shareholders Can Be Confident That Collegium Pharmaceuticals Earnings Are High Quality
Simply Wall St News at Macroaxis
over two months ago at gurufocus.com         
Collegium Pharmaceutical Inc Stock Price Down 3.72 percent on Nov 13
Gurufocus Stories at Macroaxis
a day ago at news.google.com         
Inside Cogents Next Big Move Key Presentation Set for Guggenheim Conference - StockTitan
Google News at Macroaxis
over a week ago at thelincolnianonline.com         
Cogent Biosciences Appoints James P. Geygan as Independent Director
news
over a week ago at finance.yahoo.com         
This Cogent Biosciences Insider Increased Their Holding By 2,085 percent Last Year
Yahoo News
over two weeks ago at finance.yahoo.com         
Cogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Sel...
Yahoo News
over three weeks ago at finance.yahoo.com         
Cogent Biosciences Announces Presentation at the 43rd AnnualJ.P. Morgan Healthcare Conference
Yahoo News
over a month ago at news.google.com         
Cogent Biosciences, Inc. Given Average Recommendation of Moderate Buy by Analysts - MarketBeat
Google News at Macroaxis
over a month ago at thelincolnianonline.com         
What is HC Wainwrights Estimate for COGT FY2024 Earnings?
news
over a month ago at finance.yahoo.com         
Why Is Cogent Biosciences Stock Trading Higher On Monday?
Yahoo News
over a month ago at news.google.com         
Why Is Cogent Biosciences, Inc. Among the Best Small-Cap Biotech Stocks With Massive Potential Accor...
Google News at Macroaxis
over two months ago at investing.com         
Piper Sandler stays bullish on Cogent shares, cites clinical profile strength for bezu
Investing News at Macroaxis
over a week ago at news.google.com         
Coherus BioSciencess SWOT analysis stock faces headwinds amid oncology pivot - Investing.com
Google News at Macroaxis
over two weeks ago at news.google.com         
Coherus Biosciences Announces UDENYCA Divestiture and Revenue Outlook - TipRanks
Google News at Macroaxis
over three weeks ago at www.macroaxis.com         
Disposition of 1711 shares by Bryan Mcmichael of Coherus BioSciences at 1.57 subject to Rule 16b-3
Macroaxis News
over three weeks ago at news.google.com         
Why Coherus BioSciences Stock Is Sinking Today - MSN
Google News at Macroaxis
over a month ago at investing.com         
Coherus Biosciences SWOT analysis stock faces headwinds amid transition
Investing News at Macroaxis
over a month ago at investing.com         
Coherus BioSciences director Tzoumakas to exit board
Investing News at Macroaxis
over a month ago at investing.com         
Coherus Biosciences SWOT analysis stock faces headwinds amid transition
Investing News at Macroaxis
over a month ago at thelincolnianonline.com         
Coherus BioSciences Announces Agreement to Divest UDENYCA Franchise in Deal with Intas Pharmaceutica...
news
over a month ago at investing.com         
Coherus shares surge on 558M Udenyca divestiture deal
Investing News at Macroaxis
over two months ago at zacks.com         
RDY Launches Loqtorzi Biosimilar in India for Nasopharyngeal Carcinoma
zacks News
a minute ago at benzinga.com         
IonQ, HE Equipment Services And ImmunityBio Are Among Top Mid Cap Gainers Last Week Are The Others I...
benzinga news
six days ago at news.google.com         
Revenues Not Telling The Story For Blueprint Medicines Corporation After Shares Rise 28 percent - Si...
Google News at Macroaxis
over a week ago at thelincolnianonline.com         
Insider Selling Blueprint Medicines Co. Director Sells 5,000 Shares of Stock
news
over two weeks ago at thelincolnianonline.com         
Blueprint Medicines Buy Rating Reiterated at Needham Company LLC
news
over two weeks ago at investing.com         
Blueprint Medicines SWOT analysis stock surges on Ayvakit success
Investing News at Macroaxis
over two weeks ago at gurufocus.com         
Disposition of 2250 shares by Ariel Hurley of Blueprint Medicines at 36.05 subject to Rule 16b-3
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Blueprint Medicines Corp Unveils 2025 Growth Strategy and Promising Clinical Developments
Gurufocus Stories at Macroaxis
over three weeks ago at news.google.com         
Blueprint Medicines Trading 5.7 percent Higher - Still a Buy - MarketBeat
Google News at Macroaxis
over a month ago at gurufocus.com         
Insider Sell Christina Rossi Sells Shares of Blueprint Medicines Corp
Gurufocus Stories at Macroaxis
over a month ago at thelincolnianonline.com         
Disposition of 15000 shares by Albers Jeffrey W. of Blueprint Medicines at 36.05 subject to Rule 16b...
news
a day ago at www.macroaxis.com         
Disposition of 85209 shares by Bienaime Jean Jacques of Biomarin Pharmaceutical at 83.87 subject to ...
Macroaxis News
few days ago at news.google.com         
Merit Financial Group LLC Invests 317,000 in BioMarin Pharmaceutical Inc. - MarketBeat
Google News at Macroaxis
over a week ago at finance.yahoo.com         
Here is Why Growth Investors Should Buy BioMarin Now
Yahoo News
over a week ago at thelincolnianonline.com         
BioMarin Pharmaceutical Shares Down 3 percent Whats Next?
news
over two weeks ago at finance.yahoo.com         
InflaRx Stock Rises 8 percent on Conditional EC Nod for COVID-19 Drug
Yahoo News
over two weeks ago at finance.yahoo.com         
Heres Why BioMarin Pharmaceutical is a Strong Value Stock
Yahoo News
over two weeks ago at finance.yahoo.com         
Wall Street Analysts Predict a 45.86 percent Upside in BioMarin Heres What You Should Know
Yahoo News
over two weeks ago at finance.yahoo.com         
Serna Bio Announces Scientific Advisory Board
Yahoo News
over two weeks ago at businesswire.com         
CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical Development Program ...
businesswire News
over three weeks ago at finance.yahoo.com         
CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones
Yahoo News
over a week ago at aol.com         
Will it really work Young sickle cell patient among the first to start new gene therapy
news
over two weeks ago at businesswire.com         
LE RAPPORT BLUE SHIFT DARTHUR D. LITTLE EXPLORE LIMPACT DE LIA SUR LA TRANSFORMATION DE LA RECHERCHE...
businesswire News
over two weeks ago at finance.yahoo.com         
National Resilience to lay off 120 in North Carolina
Yahoo News
over three weeks ago at news.google.com         
RBC Capital cuts Bluebird Bio stock target to 8 from 80 - Investing.com
Google News at Macroaxis
over a month ago at investing.com         
bluebird bios SWOT analysis gene therapy stock faces cash crunch amid launch
Investing News at Macroaxis
over a month ago at gurufocus.com         
Bluebird Bio Shares Surge Amid Market Activity
Gurufocus Stories at Macroaxis
over a month ago at thelincolnianonline.com         
bluebird bio, Inc. Short Interest Update
news
over a month ago at finance.yahoo.com         
Acquisition by Paulson Richard A. of 24900 shares of Bluebird Bio subject to Rule 16b-3
Yahoo News
over a month ago at businesswire.com         
bluebird bio Presents Positive Long-Term Data On LYFGENIA Gene Therapy for Sickle Cell Disease at 66...
businesswire News
over a month ago at businesswire.com         
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for -Th...
businesswire News
a minute ago at kalkinemedia.com         
Japan gives priority review status to Alzheimers drug developed by Eisai, Biogen
news
over a week ago at benzinga.com         
Looking At Biogens Recent Unusual Options Activity
benzinga news
over two weeks ago at finance.yahoo.com         
Neuromuscular Disease Therapeutics Market to grow by USD 13.7 Billion from 2025-2029, driven by nove...
Yahoo News
over two weeks ago at cnbc.com         
Bristol Myers Squibb says Alzheimers is the biggest market for new schizophrenia drug
cnbc News
over two weeks ago at statnews.com         
STAT Federal watchdog raises some concerns about the FDAs accelerated approval program
news
over two weeks ago at finance.yahoo.com         
Biogen CEO sees no burning need for more acquisitions
Yahoo News
over two weeks ago at finance.yahoo.com         
Sage Therapeutics Moves 35.1 percent Higher Will This Strength Last?
Yahoo News
over two weeks ago at finance.yahoo.com         
Biogens cold and calculated offer to buy Sage receives a mixed reaction on Wall Street
Yahoo News
over two weeks ago at finance.yahoo.com         
Top Stock Movers Now Moderna, Macys, Valero Energy, and More
Yahoo News
over two weeks ago at statnews.com         
STAT Biogen CEO confirms hes shopping for biotechs We will be doing deals
news
over a year ago at finance.yahoo.com         
Orphan Drug Market Size Share to Surpass 3199.3 Billion by 2028 Vantage Market Research
Yahoo News
few days ago at news.google.com         
Allakos Shares Plummet to All-Time Low After Lead Candidate Failure - MarketWatch
Google News at Macroaxis
over a month ago at news.google.com         
Point72 Asset Management L.P. Purchases New Position in Allakos Inc. - MarketBeat
Google News at Macroaxis
over a month ago at www.macroaxis.com         
Disposition of 32466 shares by Robert Alexander of Allakos at 1.1 subject to Rule 16b-3
Macroaxis News
over two months ago at news.google.com         
Allakos Inc. finalizes early lease termination, incurring 2.5 million in costs - Investing.com
Google News at Macroaxis
over two months ago at zacks.com         
All You Need to Know About Allakos Rating Upgrade to Buy
zacks News
over two months ago at news.google.com         
10 Health Care Stocks Whale Activity In Todays Session - Benzinga
Google News at Macroaxis
over three months ago at globenewswire.com         
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
Macroaxis News: globenewswire.com
over three months ago at news.google.com         
Allakos Market Outperform Rating Reaffirmed at JMP Securities - MarketBeat
Google News at Macroaxis
over three months ago at www.macroaxis.com         
Disposition of 45320 shares by Lee Chin Hyok of Allakos at 0.65 subject to Rule 16b-3
Macroaxis News
over three months ago at simplywall.st         
We Think Allakos Needs To Drive Business Growth Carefully
Simply Wall St News at Macroaxis
over a year ago at news.google.com         
Current and Future Analysis of Rho Kinases Inhibitor Market With New Business Strategies and Forecas...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Alphacentric Lifesci that are available to investors today. That information is available publicly through Alphacentric media outlets and privately through word of mouth or via Alphacentric internal channels. However, regardless of the origin, that massive amount of Alphacentric data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Alphacentric Lifesci news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Alphacentric Lifesci relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Alphacentric Lifesci's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Alphacentric Lifesci alpha.

Other Information on Investing in Alphacentric Mutual Fund

Alphacentric Lifesci financial ratios help investors to determine whether Alphacentric Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Alphacentric with respect to the benefits of owning Alphacentric Lifesci security.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.